Form EFFECT Rail Vision Ltd.
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 21, 2024 4:00 P.M. |
| Form: | F-3 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rail Vision to Present at the 20th Annual LD Micro Main Event, Highlighting Commercial Progress and Next-Gen Rail Safety Technology
- Acromegaly Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | OPKO Health, Amolyt Pharma, Debiopharm International, Glytech, Antisense Therapeutic
- IgA Nephropathy Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share